Gilead, Teva reach settlement in Viread patent lawsuit

Tue Feb 19, 2013 11:30pm EST

A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. REUTERS/Ronen Zvulun

A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011.

Credit: Reuters/Ronen Zvulun

Related Topics

Photo

Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

(Reuters) - Gilead Sciences Inc said it has agreed with Israel's Teva Pharmaceuticals Industries Ltd to settle a lawsuit relating to patents protecting Viread, a treatment for HIV infection and chronic hepatitis B.

As per the agreement, Gilead said Teva will be allowed to launch a generic version of Viread on December 15, 2017.

"This settlement removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation," Gilead's chief operating officer, John Milligan, said in a statement late on Tuesday.

Gilead, based in California, is the world's largest maker of branded drugs to treat the human immunodeficiency virus, the cause of AIDS.

The trial in the lawsuit, which was scheduled to begin on February 20 in a Manhattan court, has been adjourned to finalize the settlement, Gilead said.

(Reporting by Sakthi Prasad in Bangalore; Editing by Matt Driskill)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.